Subscriptions

Advertising

Resources

About Us

Contact Us

Create An Account Forgot Your Password?
Trouble logging in or creating an account? click here
Home This Month E-Weekly Newsletter Building a Facility Article Archive Second Opinions
Search:
Benchmarking
General Surgery
Accrediting/Quality
Anesthesia
Code/Bill/Reimburse
Building/Renovating
/_media/adv/web/images/2010/20100511_Arthrex_LB_154x100.gif
/_media/adv/web/images/2010/20100824_HCA_LB_154x100.gif
/_media/adv/web/images/2010/20100407_ORX_LB-01_154x100.gif
Outpatient Surgery E-Weekly

OR Excellence Pre-Registration Ends Wednesday

This Wednesday, Sept. 1, is your last chance to participate in Outpatient Surgery Magazine's OR Excellence 2010 Pre-Registration Contest. There's no...

Researchers Predict Anesthesiologist Shortage, CRNA Surplus

A recent analysis of the anesthesia labor market speculates that a current shortfall of providers across the surgical industry could widen in the ne...

A Change of Mind: Anesthesia, Consciousness and the Brain

The brain works through different processes as it transitions between conscious and unconscious states, a finding that bucks commonly held assumptio...

Home > News > June, 2009

Synthes Indicted Over Unapproved Study of Bone Cement

Federal indictment alleges that bone filler was used in spine surgeries without FDA authorization.

Synthes, the world's largest maker of implants to mend bone fractures, conducted an unapproved study of the use of its Norian XR injectable cement bone filler that led to the deaths of 3 patients during spinal surgery and then lied to the FDA about it, prosecutors said yesterday after a federal grand jury in Philadelphia handed down a 52-count indictment.

Prosecutors allege that between 2002 and 2004, Synthes and its subsidiary, Norian, conspired to conduct unauthorized clinical trials on 2 versions of the product in spinal surgeries to treat vertebral compression fractures — an application of the bone filler explicitly prohibited by the FDA, according to a published report. The 3 patients who allegedly died during the trials died from rapid drop in blood pressure. The company marketed the cement for spinal fractures even after pilot studies showed it caused blood clots that could become lodged in the lungs, prosecutors said.

"Synthes has fully cooperated with the government’s investigation," and "believes that its marketing practices in connection with Norian XR were proper," a Synthes spokesman says in a statement. Synthes "intends to vigorously defend itself against the charges," he said.

The indictment includes 52 felony counts against California-based Norian, 44 misdemeanor counts against its Switzerland-based parent company, Synthes Inc., and 1 criminal misdemeanor count each for 4 Synthes executives accused of shipping an adulterated and misbranded product.

The indictment also accuses the companies of "allegedly carrying out a cover-up in which they lied to the FDA during an official inspection in May and June 2004." In a statement, U.S. Attorney Michael Levy says the companies and executives "put their profits ahead of responsible business practices and the truth."

Synthes, with North American offices located in West Chester, Pa., acquired Norian in 1998. If found guilty, Norian could face $28 million in fines; Synthes could face $8 million in fines; and the 4 executives charges could face 1-year prison sentences.

Irene Tsikitas

Categories: Legal/Regulatory, Product Reports, News
Already have an account? Please sign in:
Email Address:
Password:
PRODUCT & SERVICE RESOURCES
Product & Service Showcase
A showcase of products and services geared to make your facility better.
Professional Services Platinum Pages
A guide of people and companies to help make your facility better.
Other Articles That May Interest You
Woodrum/ASD Fails to Recover Funds From Bankrupt ASC
Management firm tried to collect from failed surgery center's owner.
S.C. Hospital Found Guilty of Stark Violations
Judge could order hospital to pay $44.8 million in damages.
ACL Reconstruction Rates Increasing
Researchers say the procedures should be performed at high-volume facilities by experienced surgeons.